Dengue human infection model performance parameters.

Dengue is a global health problem and of concern to travelers and deploying military personnel with development and licensure of an effective tetravalent dengue vaccine a public health priority. The dengue viruses (DENVs) are mosquito-borne flaviviruses transmitted by infected Aedes mosquitoes. Illness manifests across a clinical spectrum with severe disease characterized by intravascular volume depletion and hemorrhage. DENV illness results from a complex interaction of viral properties and host immune responses. Dengue vaccine development efforts are challenged by immunologic complexity, lack of an adequate animal model of disease, absence of an immune correlate of protection, and only partially informative immunogenicity assays. A dengue human infection model (DHIM) will be an essential tool in developing potential dengue vaccines or antivirals. The potential performance parameters needed for a DHIM to support vaccine or antiviral candidates are discussed.

[1]  D. Henderson,et al.  Inactivated Measles Virus Vaccine , 1962, Public health reports.

[2]  J. Oxford,et al.  Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study. , 2011, The Journal of infectious diseases.

[3]  A. Sabin Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.

[4]  C. Andrewes,et al.  Influenza: Observations on the Recovery of Virus from Man and on the Antibody Content of Human Sera , 1935 .

[5]  A. A. Smorodintseff,et al.  INVESTIGATION ON VOLUNTEERS INFECTED WITH THE INFLUENZA VIRUS , 1937 .

[6]  Chun-Yu Lin,et al.  Classification of dengue: the clinical use of World Health Organization 2009 guideline. , 2013, Journal of the Formosan Medical Association = Taiwan yi zhi.

[7]  D. Vaughn,et al.  Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. , 2013, The Journal of infectious diseases.

[8]  J. Oxford,et al.  Potential role of human challenge studies for investigation of influenza transmission. , 2011, The Lancet. Infectious diseases.

[9]  Saravudh Suvannadabba,et al.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial , 2012, The Lancet.

[10]  B. Berliner,et al.  Inactivated measles virus vaccine. Subsequent challenge with attenuated live virus vaccine. , 1963, JAMA.

[11]  F. Spencer,et al.  Tracheostomy: An Underrated Surgical Procedure , 1963 .